Clinical strategies for the management of cytomegalovirus infection and disease in allogeneic bone marrow transplant

Bone Marrow Transplantation

Volumn 19, Issue 2, 1997, Pages 135-142

  Prentice, H G ^a   Kho, P ^b  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Bone marrow transplant; Cytomegalovirus; Pre emptive therapy; Prophylaxis

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; GANCICLOVIR;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALIC INCLUSION BODY DISEASE; DRUG SAFETY; HLA MATCHING; HUMAN; INFECTION PREVENTION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; META ANALYSIS; MORTALITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RISK FACTOR; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 0031014154     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700630     Document Type: Article

References (27)

1. Meyers JD, Flournoy N, Thomas ED. Risk factor for cytomegalovirus infection after human marrow transplantation. J Infect Dis 1986; 153: 478-488.
2. Meyers JD, McGuffin RW, Neiman PE et al. Toxicity and efficacy of human leukocyte interferon for treatment of cytomegalovirus pneumonia after marrow transplantation. J Infect Dis 1980; 141: 555-562.
3. Meyers JD, McGuffin RW, Bryson YJ et al. Treatment of cytomegalovirus pneumonia after marrow transplant with combined vidarabine and human leukocyte interferon. J Infect Dis 1982; 146: 80-84.
4. Wade JC, Hintz M, McGuffin RW et al. Treatment of cytomegalovirus pneumonia with high-dose aciclovir. Am J Med 1982; 73 (Supp. 1A): 249-256.
5. Emmanuel D, Cunningham I, Jules-Elysee K et al. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. Ann Intern Med 1988; 109: 777-782.
6. Reed EC, Bowden RA, Dandliker PS et al. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplant. Ann Intern Med 1988; 109: 783-788.
7. Grundy JE, Shanley JD, Griffiths PD. Is cytomegalovirus interstitial pneumonitis in transplant recipients an immunopathological condition? Lancet 1986; 335: 996-999.
8. Bowden RA, Sayers M, Flournoy N et al. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. New Engl J Med 1986; 314: 1006-1010.
9. Meyers JD, Reed EC, Shepp DH et al. Aciclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. New Engl J Med 1988; 318: 70-75.
10. Prentice HG, Gluekman E, Powles RP et al. The impact of long-term aciclovir on cytomegalovirus infection and survival in allogeneic bone marrow transplantation. Lancet 1994; 343: 749-753.
11. Goodrich JM, Bowden RA, Fisher L et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogenic marrow transplant. Ann Intern Med 1993; 118: 173-178.
12. Winston DJ, Ho WG, Bartoni RN et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Ann Intern Med 1993; 118: 179-184.
13. Atkinson K, Downs K, Goleria M et al. Prophylactic use of ganciclovir in allogeneic bone marrow transplantation: absence of clinical cytomegalovirus infection. Br J Haematol 1991; 79: 57-62.
14. Von Bueltzingsloewen A, Bordigoni P, Witz F et al. Prophylactic use of ganciclovir for allogeneic bone marrow transplant recipients. Bone Marrow Transplant 1993; 12: 197-202.
15. Goodrich JM, Mori M, Cleaves CA et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. New Engl J Med 1991; 325: 1601-1607.
16. Schmidt GM, Horak DA, Niland JC et al. A randomised, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplant. New Engl J Med 1991; 324: 1005-1011.
17. Ljungman P, DeBock R, Cordonier C et al. Practices for cytomegalovirus diagnosis, prophylaxis and treatment in allogeneic bone marrow transplant recipients; a report from the Working Party for Infectious Diseases of the EBMT. Bone Marrow Transplant 1993; 12: 399-403.
18. Aschan J, Ringden O, Ljungman P et al. Foscarnet for treatment of cytomegalovirus infection in bone marrow transplant recipients. Scand J Infect Dis 1992; 24: 143-150.
19. Shepp DH, Dandliker PS, de-Miranda P et al. Activity of 9-(2-hydroxy 1-(hydroxymethyl) ethoxymethyl) guanine in the treatment of cytomegalovirus pneumonia. Ann Intern Med 1985; 103: 368-272.
20. Ettinger NA, Selby P, Powles R et al. Cytomegalovirus pneumonia: the use of ganciclovir in marrow transplant recipients. J Antimicrob Chemother 1989; 24: 53-62.
21. Selby P, Powles RL, Jameson B et al. Treatment of cytomegalovirus pneumonia after bone marrow transplantationn with 9-(2-hydrox-1-(hydroxymethyl) ethoxymethyl) guanine. Lancet 1986; i: 1377-1378.
22. Crumpacker C, Marlowe S, Zhang JL et al. Treatment of cytomegalovirus pneumonia. Rev Infect Dis 1988; 10 (Suppl. 3): 538-546.
23. Ljungman P, Engelhard D, Link H et al. Treatment of interstitial pnuemonitis due to cytomegalovirus with ganciclovir and intravenous immune globulin: experience of European Bone Marrow Transplant Group. Clin Infect Dis 1992; 14: 831-835.
24. Reed EC, Wolford JL, Kopecky KJ et al. Ganciclovir for the treatment of cytomegalovirus gastroenteritis in bone marrow transplant patients. A randomised, placebo-controlled trial. Ann Intern Med 1990; 112: 505-510.
25. Chang J, Powles R, Mehta J. Foscarnet treatment for CMV viraemia in allo-BMT recipients. Br J Cancer 1995; 71 (Suppl. XXIV): 69.
26. Bacigalupo A, Tedone E, Van Lint MT et al. CMV prophylaxis with foscarnet in allogeneic bone marrow transplant recipients at high risk of developing CMV infections. Bone Marrow Transplant 1994; 13: 783-788.
27. Meyers JD, Ljungman P, Fisher LD. Cytomegalovirus excretion as a predictor of cytomegalovirus disease after marrow transplantation: the importance of cytomegalovirus viraemia. J Infect Dis 1990; 162: 373-380.